Form 4: Rigel Pharmaceuticals EVP, Chief Medical Officer Lisa Rojkjaer Reports Stock Option Grant

Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reports the acquisition of stock options.

Summary

• Lisa Rojkjaer, the EVP and Chief Medical Officer of Rigel Pharmaceuticals, filed a Form 4 on March 29, 2024, reporting a transaction.
• On March 27, 2024, Rojkjaer acquired 187,500 employee stock options with an exercise price of $1.49.
• These options vest over time, with one-fourth vesting on March 11, 2025, and the remainder vesting monthly over the subsequent 36 months, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The grant of stock options to a key executive like the Chief Medical Officer can be seen as an incentive to align their interests with the long-term success of the company.

Future Outlook

The vesting schedule of the options incentivizes the reporting person to remain with the company for the vesting period.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are typically structured to incentivize long-term performance and retention.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, potentially driving long-term value creation.

Key Dates